Diademdx
1 known investors
Diadem is a diagnostics company developing AlzoSure, a plasma/blood-based test that uses a proprietary antibody targeting a specific conformation of the p53 protein to predict and diagnose Alzheimer's disease. The test aims to provide early, non-invasive diagnosis and to support patient recruitment for Alzheimer's drug development clinical trials.
BiotechDigital HealthMedical Devices
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.